- Details
- In this UroToday discussion between Charles Ryan and Mark Markowski, they focus on Dr Markowski’s recent study, entitled COMAT-CRPC. The COMBAT-CRPC study is a study with bipolar androgen therapy and nivolumab, which was conducted through the Prostate Cancer Clinical Trials Consortium. Dr. Markowski begins by discussing the criteria for patient eligibility, which was quite broad, which was to be a...
|
- Details
- In this discussion, Alicia Morgans and Terence Friedlander discuss updates from the EV-103 study. The EV-103 study is a phase one/two clinical trial that looked at the combination of enfortumab vedotin and pembrolizumab in, previously treated, patients with cisplatin-ineligible, metastatic urothelial cancer. Historically, cisplatin-ineligible metastatic urothelial cancer patients have had a very p...
|
- Details
- In this informative presentation from Andrea Necchi, MD, he presents information related to his goal of finding bladder-sparing treatment options for muscle-invasive bladder cancer (MIBC). Dr. Necchi begins his presentation with a discussion on recent immunotherapy studies for MIBC, the Balar, and IMMUNOPRESERVE studies. He presents evidence that both of these trials have displayed a promising amo...
|
- Details
- In this conversation, Rana McKay and Andrea Apolo highlight several studies presented during the ASCO 2021 Annual Meeting on combination therapeutic options for advanced renal cell carcinoma (RCC). Dr. Apolo expands on several studies she highlighted in her presentation and where these treatment options fit into the treatment landscape of advanced RCC potentially enhancing the immune effect of imm...
|
- Details
- In an educational session at the 2021 ASCO annual meeting, Elisabeth Heath, MD, FACP, discussed the variability of treatment options offered to patients with prostate cancer based on patients’ race and geographic location. In this conversation between Charles Ryan, MD, and Dr. Heath, the topic of clinical trial inclusion biases is brought to the forefront. The blindly accepted idea that Black men...
|
- Details
- In an abstract review session at the 2021 ASCO annual meeting, Lisa Horvath, PhD, MBBS, FRACP, reviewed 3 abstracts: PEACE-1, the SWOG S1216 trial, and the PEACE-III trial. She expanded her conversation about these three abstracts in a discussion with Alicia Morgans, MD, MPH. In the primary conversation about the PEACE-1 trial, Dr. Horvath discussed the main interest, in this phase III trial, to b...
|
- Details
- The SWOG S1216 is a Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (mHSPC). Tak is an oral selective nonsteroidal 17, 20-lyase inhibitor that blocks the synthesis of gonadal and adrenal androgens and in this trial the clinical benefit of Tak wi...
|
- Details
- Alicia Morgans and Phuoc Tran explore the intricacies of treating oligometastatic prostate cancer, focusing on high-risk patients identified through advanced PSMA-based imaging. Originating from ASCO 2021 case-based discussions, they emphasize the need to reconcile modern imaging data with historical treatment evidence. Dr. Tran notes that these high-risk patients may benefit from hormone therapy...
|
- Details
- In this conversation with Alicia Morgans, Silke Gillessen highlights the bone health analysis evaluating the combination of enzalutamide and radium or enzalutamide alone might affect bone health and fracture rate within patients with metastatic castration-resistant prostate cancer. At the 2021 ASCO meeting, Dr. Gillessen presented an updated safety analysis from the EORTC 1333 / PEACE III trial of...
|
- Details
- Charles Ryan interviews Elena Castro and Fernando Lopez-Campos. They delve into their real-world data on the management of metastatic castration-resistant prostate cancer (mCRPC) in Spain, specifically focusing on the impact of early PSA progression on overall survival in patients treated with enzalutamide or abiraterone. Drs. Castro and Lopez-Campos discuss the significance of monitoring PSA leve...
|
